Publication:


abstract

Since several years, the perception of lung cancer has considerably evolved. Indeed, we have proceeded from a simple classification based on histology to a molecular dismemberment, with a lot of subtypes of tumors according to there molecular alteration profile. Mutations of the EGFR receptor define so a group of cancers particularly sensitive to EGFR tyrosine kinase inhibitors (TKI). Gefitinib has shown its efficacy in term of response and survival in first line treatment of NSCLC arboring EGFR mutations. Recently, the ALK-AML4 translocation has been found in approximately 5% of NSCLC, accessible to a specified targeted therapy (crizotinib) with response rate around 60%. NSCLC with HER2 mutation or amplification could be treated with trastuzumab, whereas treatments targeting Met pathway are currently in development. At last, several drugs active in case of DNA repair dysfunction, like PARP inhibitors, have already shown there efficacy in particular types of NSCLC. In a very near future, molecular screening of these molecular alterations should be systematic from the diagnostic, to allow a personalized treatment according to the mutation profile.

Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Related Articles
[What choice of first-line treatment?].
Rev Pneumol Clin. 2011
[What choice of first-line treatment?].
Moro-Sibilot D. Rev Pneumol Clin. 2011 Jun; 67 Suppl 1:S20-3.
[What is the best sequence of treatment for patients with EGFR mutations?].
Rev Pneumol Clin. 2011
[What is the best sequence of treatment for patients with EGFR mutations?].
Besse B, Zalcman G. Rev Pneumol Clin. 2011 Jun; 67 Suppl 1:S24-9.
[Management of patients with resistance to EGFR-TKI].
Rev Pneumol Clin. 2011
[Management of patients with resistance to EGFR-TKI].
Barlesi F. Rev Pneumol Clin. 2011 Jun; 67 Suppl 1:S30-5.
Review Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
J Clin Oncol. 2010
Review Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. J Clin Oncol. 2010 Nov 1; 28(31):4769-77. Epub 2010 Oct 4.
Review Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Drug Resist Updat. 2011
Review Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M, Stordal B. Drug Resist Updat. 2011 Jun; 14(3):177-90. Epub 2011 Mar 24.